Studies of biomarkers in CSF of AD patients show a continuous decline in levels of soluble Aβ monomers that parallels cortical amyloid plaque deposition, followed by a gradual increase in phosphorylated tau (p-tau) levels [13,14,15]. This evidence concerns the gene MAPT and Alzheimer disease.